Font: Financial Modeling Prep • Feb 24, 2026
Enhabit, Inc. (NYSE:EHAB) is currently under the spotlight due to a proposed sale to Kinderhook Industries, LLC. UBS has set a price target of $13.80 for EHAB, which is slightly above its current trading price of $13.60. This suggests a potential price increase of about 1.47%, indicating a relatively stable outlook for the stock.
The proposed transaction involves Enhabit shareholders receiving $13.80 per share in cash. This aligns with UBS's price target, suggesting that the market has already factored in the potential sale price. Kahn Swick & Foti, LLC is investigating the fairness of this deal, focusing on whether the financial terms and the process are adequate for shareholders.
EHAB has seen a notable increase in its stock price, rising by 22.63%, or $2.51. This surge reflects investor optimism, possibly driven by the proposed sale. The stock's price today has ranged from $13.55 to $13.64, with the latter being its highest in the past year, indicating strong market interest.
The market capitalization of EHAB is approximately $689.4 million, reflecting the company's overall value in the stock market. With a trading volume of 12.6 million shares, there is significant activity and interest in EHAB, likely influenced by the ongoing investigation and the proposed sale.
|
TZA§>
Direxion Daily Small Cap Bear 3X ETF
|
$4.83
-7.29%
|
|
SLXN§>
Silexion Therapeutics Ltd.
|
$0.53
96.95%
|
|
HAO§>
Haoxi Health Technology Limited
|
$0.01
0.71%
|
|
SOXS§>
Direxion Daily Semiconductor Bear 3X ETF
|
$8.54
-14.00%
|
|
MEHA§>
Functional Brands, Inc. Common Stock
|
$0.09
21.95%
|
|
JUNS§>
Jupiter Neurosciences, Inc.
|
$0.21
-35.94%
|
|
PHGE§>
BiomX Inc.
|
$0.60
59.60%
|
|
WOK§>
WORK Medical Technology Group Ltd.
|
$0.19
-19.57%
|
|
HCWB§>
HCW Biologics Inc.
|
$2.43
129.25%
|
|
GDC§>
GD Culture Group Limited
|
$0.12
-17.44%
|